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The role of allogeneic stem cell transplantation (SCT) in the management of aggressive non-Hodgkin lym-
phoma (NHL) remains to be deﬁned, but the number of procedures performed continues to increase. We
report here the outcomes of allogeneic SCT using carmustine, etoposide, cytarabine, and melphalan (BEAM)-
Campath (Genzyme Corporation, Cambridge, MA) conditioning for aggressive NHL as reported to the British
Society of Blood and Marrow Transplantation (BSBMT). This retrospective study identiﬁed 46 patients who
reported to the BSBMT registry as having undergone BEAM-Campath conditioned allogeneic SCT for
aggressive NHL between 1999 and 2010. Disease histology was diffuse large B cell lymphoma (DLBCL, n ¼ 25),
DLBCL/Burkitt lymphoma (n ¼ 5), and T cell lymphoma (n ¼ 16). At diagnosis, the median age was 42.5 (range,
17 to 59), 37 had advanced stage disease (Ann Arbor III/IV), 28 had 2 or more extra-nodal sites of disease, and
23 had elevated lactate dehydrogenase. International prognostic index was high or high/intermediate in 58%.
The median number of prior therapies was 3 (range, 1 to 5) and 5 patients had previously undergone
transplantation (4 autologous, 1 allogeneic). The median age at transplantation was 44.8 (range, 18 to 59),
with 34 patients demonstrating chemo-sensitive disease and 22 undergoing transplantation in ﬁrst response.
Performance score was good in 40 patients and all engrafted with a median of 14 days (range, 11 to 27) to
neutrophil recovery. At latest follow-up, 20 patients were alive with 17 in complete remission. Acute graft-
versus-host disease (GVHD) developed in 7 patients and chronic GVHD developed in 13 (7 limited, 6
extensive). Five patients died from nonrelapse causes, with a cumulative incidence of nonrelapse mortality of
7% at 100 days and 11% at 3 and 5 years. Twenty-one patients died after lymphoma relapse, with a cumulative
incidence of relapse/progression of 51% at 1 year and 53% at 5 years. Disease status at transplantation had no
impact on relapse rate. Progression-free survival was 41% at 1 year and 36% at 5 years. Overall survival was
54% at 1 year and 42% at 5 years. Overall, BEAM-Campatheconditioned allogeneic SCT is well tolerated and
able to deliver durable disease-free survival to a subset of patients with aggressive NHL. However, the high
relapse rates indicate further investigation is needed to identify those patients most likely to beneﬁt.
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Aggressive histology non-Hodgkin lymphoma (NHL)
includes high-grade B cell lymphomas and peripheral T cell
lymphomas (PTCL), which have the potential to be cured
with combination chemotherapy.
Table 1
Patient and Disease Characteristics
Characteristic Value
No. of patients 46
Diagnosis
DLBCL 25
DLBCL/Burkitt’s lymphoma 5
Peripheral T cell lymphoma NOS 13
Anaplastic large cell lymphoma 2
Angioimmunoblastic T cell lymphoma 1
Sex (male/female) 27/19
Age at diagnosis, median (range), yr 42.5 (17-59)
Stage at diagnosis, n
I/II 4
III/IV 37
Unknown 5
B symptoms 32
Prior lines of therapy, median (range) 2.5 (1-5)
Prior transplantation 5
Autologous 4
Allogeneic 1
Diagnosis to transplant, median (range), yr .9 (.25-13.9)
Disease status at transplantation
CR 15
Partial remission/VGPR 19
Primary refractory 4
Relapsed 7
Unknown 1
NOS indicates not otherwise speciﬁed; VGPR, very good partial remission.
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lymphoma (DLBCL) have improved with the addition of
rituximab to initial chemotherapy [1,2], a signiﬁcant minor-
ity of patients still experience relapse [3,4]. The role of
high-dose therapy (HDT) followed by autologous stem cell
transplantation (ASCT) in relapsed diseasewas established in
the pre-rituximab era [5]. However, those relapsing after or
refractory to immuno-chemotherapy have a poor outcome
with conventional salvage followed by HDT/ASCT [6].
PTCL comprise a heterogeneous group of NHL that tend to
have more aggressive disease characteristics at presentation
than their B cell counterparts. With the exception of
anaplastic lymphoma kinaseepositive anaplastic large cell
lymphoma, the outcomes with anthracycline-based chemo-
therapy are worse than those for B NHL and the gold
standard front-line combination chemotherapy remains to
be deﬁned [7-9]. The overall poor prognosis for patients with
PTCL has led to use of HDT/ASCT to consolidate ﬁrst
responses [10-12], with more promising results.
The role of HDT/ASCT in themanagement of patients with
aggressive NHL is clearly changing and alternative strategies
are required in the management of some patients with high-
risk features and those with relapsed disease. Although the
optimal role for allogeneic stem cell transplantation (SCT)
remains to be established in aggressive NHL, the number of
procedures performed has signiﬁcantly increased in recent
years [13]. Allogeneic SCT offers the advantages of a tumor-
free graft, the potential for a donor-derived immune
cellemediated graft-versus-lymphoma (GVL) effect, and a
lower risk of relapse when compared with ASCT [14].
Concern over the risk of nonrelapse mortality (NRM) with
conventional myeloablative regimens in aggressive NHL has
led to the introduction of reduced-intensity conditioning
(RIC) with variable success [15-17].
The less-intensive RIC regimens rely on the potential GVL
effect for long-term disease control, but the evidence to
support such an effect is less compelling in aggressive NHL
than in low-grade disease [18]. Therefore, the antilymphoma
efﬁcacy of the conditioning chemotherapy is an important
consideration in the development of such regimens. The
BEAM (carmustine, etoposide, cytarabine, and melphalan)
regimen is widely used to condition ASCT with efﬁcacy and
acceptable toxicity and is more intensive than other RIC
approaches with the potential for improved disease control
[15]. In the United Kingdom, BEAM is commonly combined
with the anti-CD52 monoclonal antibody Campath (Gen-
zyme Corporation, Cambridge, MA), which is sufﬁciently
immunosuppressive to allow donor stem cell engraftment, to
condition patients with lymphoproliferative disease before
allogeneic SCT [19,20]. We report here the outcome of pa-
tients with aggressive NHL conditionedwith BEAM-Campath
before allogeneic SCT as reported to the British Society of
Blood and Marrow Transplantation (BSBMT).
METHODS
Data Collection and Study Population
The patients analyzed in this study were retrospectively identiﬁed from
the BSBMT registry. The BSBMT is responsible for the collection and coor-
dination of data submission on all transplantations performed by the 55
member centers in the United Kingdom and the Republic of Ireland each
year and ensures that annual follow-up data on all patients are submitted to
the registry. It is also responsible for the submission of data on all United
Kingdom transplantations to the European Group for Blood and Marrow
Transplantation.
The study population included all adult patients (>18 years) with a
diagnosis of aggressive histology NHL who had received a BEAM-Cam-
patheconditioned allogeneic SCT in a UK center as reported to the BSBMTbetween 1999 and 2010. The analysis identiﬁed 46 patients who underwent
transplantation at 6 UK centers. All patients received carmustine (BCNU)
300 mg/m2 on day 6, etoposide 200 mg/m2 on days 5 to 2, cytarabine
400 mg/m2 on days 5 to2, and melphalan 140 mg/m2 on day -1 together
with Campath-1H (alemtuzumab) 10 mg (n ¼ 44) or 20 mg (n ¼ 2) on
days 5 to 1. Cyclosporin was administered for 90 days after trans-
plantation for graft-versus-host disease (GVHD) prophylaxis.
Endpoints and Deﬁnitions
The primary aim of this study was to report the outcomes of patients
with aggressive NHL after BEAM-Campatheconditioned allogeneic SCT. The
analysis included patient and disease characteristics; transplantation char-
acteristics; time to neutrophil engraftment; and incidences of acute and
chronic GVHD, NRM, relapse, progression-free survival (PFS), and overall
survival (OS). Histologic diagnosis was based on local review, classiﬁed ac-
cording to the World Health Organization criteria [21]. Disease status was
deﬁned according to International Workshop criteria for NHL [22].
Neutrophil engraftment was deﬁned as the ﬁrst of 3 consecutive days with
an absolute neutrophil count  .5  109/L. Acute and chronic GVHD were
deﬁned and graded as per published criteria [23,24]. The incidence of
chronic GVHD was calculated in patients surviving beyond 100 days and
classiﬁed as none, limited, or extensive. NRMwas deﬁned as death from any
cause without evidence of progression/relapse of lymphoma. Relapse was
deﬁned as disease progression after a complete remission (CR). PFS was
measured from the time of transplantation to relapse (patients in CR),
progression (patients in partial remission), death from any cause, or last
follow-up. OS was deﬁned as the time from transplantation to the date of
death from any cause or last follow-up.
Statistical Analysis
Patient, disease, and transplantation characteristics (Tables 1, 2) were
recorded with the median and range for continuous variables and per-
centage for categorical data. Cumulative incidence estimates were used for
NRM and relapse. PFS and OS estimates were calculated using the Kaplan
Meier method. Patient, disease, and transplantation characteristics were
studied for associations with patient outcomes by univariate analysis and
multivariate analysis using the log-rank test and Cox regression analysis
respectively.
RESULTS
Patient and Transplantation Characteristics (Tables 1, 2)
The analysis identiﬁed 46 patients with a median age at
diagnosis of 42.5 years. Disease histology included DLBCL,
DLBCL/Burkitt’s lymphoma, and PTCL with 13 patients
Table 2
Transplantation Characteristics
Characteristics Value
Age at transplantation, median (range), yr 44.8 (18-59)
Donor relationship
Matched sibling 32
Matched unrelated donor 11
Mismatched unrelated 3
Stem cell source
Peripheral blood stem cells 42
Bone marrow stem cells 4
Performance status at transplantation
Karnofsky > 80 40
Karnofsky < 80 2
Unknown 4
CMV serostatus at transplantation, n (%)
Recipient negative/donor negative 15 (33)
Recipient positive/donor negative 13 (28)
Recipient negative/donor positive 5 (11)
Recipient positive/donor positive 12 (26)
Unknown 1 (2)
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the DLBCL/Burkitt’s lymphoma patients, 1 was classiﬁed as
Burkitt lymphoma and 4 as high-grade B cell lymphoma/
Burkitt-like lymphoma, and all underwent transplantation
at ﬁrst relapse. At the time of diagnosis, 37 patients had
advanced stage (Ann Arbor III/IV) disease, 28 had 2 or more
extra-nodal sites of disease, and 23 elevated lactate dehy-
drogenase. The international prognostic index was high or
high-intermediate in 58% of evaluable patients. A median of
2.5 prior lines of therapy had been received by the study
population, with 11 of the 29 patients with B cell NHL having
been previously exposed to rituximab. Five patients had
undergone a prior transplantation procedure (4 autologous,1
allogeneic).
The median age at the time of transplantation was
44.8 years, with a median time from diagnosis to trans-
plantation of .9 years. At the time of allogeneic SCT, 34 pa-
tients demonstrated chemo-sensitive disease, with 22
undergoing the procedure in ﬁrst response. The majority of
patients in this study, 41 out of 46, underwent allogeneic SCT
as their ﬁrst transplantation procedure because they were
considered to have a poor outlook with HDT/ASCT. All
patients who underwent transplantation in ﬁrst response
were refractory to front-line therapy and those who under-
went transplantation at ﬁrst relapse had progressed early
and/or been refractory to initial salvage therapy. The Kar-
nofsky performance score was good (>80) in 40 of the 46
patients at transplantation. Peripheral blood stem cells were
mobilized using granulocyte colonyestimulating factor from
42 donors, with the remaining 4 donors providing bone
marrow stem cells. The donors were HLA-identical siblings
(10/10), HLA-identical volunteer unrelated donors (VUD) (10/
10), or HLA-mismatched VUD (9/10). No patient received a
transplant from a donor with more than 1 antigen mismatch.
Cytomegalovirus (CMV) status was matched between donor
and recipient in 27 transplantations and was unknown in 1.Figure 1. NRM after allogeneic transplantation with BEAM-alemtuzumab
conditioning for NHL.Engraftment, GVHD, and Toxicity
No patient experienced primary graft failure, with all 46
engrafting with a median time to neutrophil recovery of
14 days (range, 11 to 27). Donor lymphocyte infusion (DLI)
was subsequently used in 10 patients; 4 received DLI for
mixed chimerism, 5 for treatment failure, and 1 for an
unknown indication. Eight patients experienced late graftfailure; 4 received sibling donor cells and 4 VUD transplants,
and 5 of these donorsweremale. Acute GVHD of grade II to IV
occurred in 7 patients (15%) and was the primary cause of
death in 1 patient. Chronic GVHD occurred in 13 of the 37
patients (35%) surviving beyond 100 days after trans-
plantation and was limited in 7 patients and extensive in 6.
There were 4 other transplantation-related deaths, with 3
due to infectious causes (1 bacterial and fungal, 1 fungal, and
1 viral) and 1 due to respiratory failure. CMV reactivationwas
identiﬁed in 7 patients. A total of 5 patients died of
transplantation-related causes with the cumulative
incidence of NRM of 7% at 100 days and 11% (95% conﬁdence
interval [CI], 2% to 20%) at 3 and 5 years after transplantation
(Figure 1). The univariate analysis identiﬁed that NRM was
signiﬁcantly higher for thosewith a poor performance status,
a VUD, a prior transplantation procedure, and for those
exposed to 3 or more prior lines of therapy. The 3-year NRM
for sibling donor transplant recipients was 3% versus 30% for
VUD transplant recipients, P ¼ .042 (Figure 2). Performance
status and donor type remained signiﬁcant in terms of NRM
on the multivariate analysis (Table 3).Relapse, PFS, and OS
At last follow-up, 20 patients were alivewith 17 in CR. The
remaining 26 patients had died: 21 after lymphoma relapse
(20 from progressive lymphoma and 1 with viral encepha-
litis) and 5 from NRM. The cumulative incidence of lym-
phoma progression/relapse at 1 and 5 years after SCT was
51% and 53% (95% CI, 38% to 68%), respectively (Figure 3).
Chimerism levels were available for 14 of the relapsing
patients and did not predict relapse, with 8 having full donor
chimerism and 6 havingmixed chimerism. DLI was given to 5
of the patients with lymphoma relapse: 1 achieved a CR and
the others did not respond.
Relapse was associated with use of a sibling donor in the
univariate analysis (5-year relapse rate 63% versus 31%,
P ¼ .047) but not in the multivariate analysis. PFS was 41%
and 36% at 1 and 5 years after SCT, respectively (Figure 4),
with a trend towards longer PFS in patients < 45 years of age
(5-year PFS, 51% versus 22%, P ¼ .06). The 100-day mortality
rate was 20% with OS of 54% at 1 year and 42% (95% CI, 28% to
56%) at 5 years (Figure 5). OS was improved in CMV-negative
Figure 2. NRM after allogeneic transplantation with BEAM-alemtuzumab
conditioning for NHL by type of donor.
Figure 3. Relapse rate after allogeneic transplantation with BEAM-
alemtuzumab conditioning for NHL.
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31%, P ¼ .028), but this lost signiﬁcance in the multivariate
analysis. Disease status at transplantation had no impact on
relapse rate, PFS, or OS.DISCUSSION
Allogeneic SCT is a potentially curative therapy in the
management of aggressive NHL and the use of RIC regimens
has increased the number of patients eligible for this
approach. The BEAM regimen has been shown to be effective
lymphoma therapy with low toxicity when used to condition
both autologous and allogeneic SCT for lymphoproliferative
disorders [19,20,25]. The addition of Campath in the alloge-
neic setting provides sufﬁcient immunosuppression via T cell
depletion to facilitate engraftment while reducing the risk of
GVHD [16,19,20].
This retrospective analysis of the United Kingdom’s
experience of BEAM-Campatheconditioned allogeneic SCT
for aggressive NHL conﬁrms that the procedure is well
tolerated with acceptable levels of toxicity. We included all
patients with aggressive histology NHL, both B and T
phenotype, as this is the patient population with high-grade
lymphoproliferative disorders in whom the BEAM-Campath
regimen is employed and historical data on allogeneic SCT
has tended to analyze these histologies as a group. Overall,
the outcome for the 46 patients identiﬁed in this analysis is a
5-year PFS of 36% and OS of 42%. These outcomes are
comparable to those reported from other registry data as
well as those from series of relapsed/refractory aggressive
NHL patients, which included myeloablative trans-
plantations [26-29]. The outcomes reported here alsoTable 3
Multivariate Analysis
Risk Factor HR 95% CI P Value
No. of prior lines .964 .335-2.776 .946
Performance status at Tx 4.804 3.653-6.320 .001
Donor N - .001
Prior transplantation 5.267 .218-127.5 .307
HR indicates hazard ratio; Tx, treatment.
Bold indicates statistical signiﬁcance.compare favorably with those reported for ﬂudarabine-
based RIC allogeneic SCT in aggressive NHL with 2 to
3-year OS ranging between 34% and 47% [15,16]. The main
barrier to transplantation success in this cohort was relapsed
disease, with a cumulative incidence of 53% at 5 years. High
relapse rates have been a consistently reported feature with
RIC regimens in aggressive NHL [15,16]. Lymphocyte
recovery and, hence, immune reconstitution are delayed
after T cell depletion with Campath-containing regimens
[30]. This has resulted in concerns regarding the risk of
relapse due to the likely negative impact on the potential for
a GVL effect when T cell depletion is incorporated into RIC
protocols [17]. Morris et al. identiﬁed disease status at
transplantation as having a signiﬁcant impact on outcome in
transplantations incorporating T cell depletion [16]. RIC
allogeneic SCT with T cell depletion places a greater
emphasis on lymphoma control in the pretransplantation
setting and after transplantation with the use of immuno-
therapeutic interventions. There is evidence to support a GVLFigure 4. PFS after allogeneic transplantation with BEAM-alemtuzumab con-
ditioning for NHL.
Figure 5. OS after allogeneic transplantation with BEAM-alemtuzumab con-
ditioning for NHL.
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suppression and DLI reported and long-term disease control
achieved [14,31,32]. The observation that RIC allogeneic SCT
can achieve durable disease control in patients who have
relapsed after a previous ACST is further evidence of a GVL
effect in aggressive NHL [33]. In this series, a complete
response to DLI was seen in 1 of the 5 patients treated for
relapse/progression. The rapid growth kinetics of aggressive
NHL may allow the malignant clone to escape the potential
GVL effect and, at least in part, explain the higher relapse
rates seen after allograft when compared with indolent
histologies [34].
Although relapsewas problematic in this series, therewas
no association with disease status at transplantation, a
ﬁnding consistent with a previous multi-center report of
BEAM-Campatheconditioned transplantations [19]. In fact,
no variable was found to be signiﬁcantly associated with an
increased relapse risk, with the association with use of a
sibling donor losing signiﬁcance in the multivariate analysis.
This may reﬂect the impact of improved lymphoma control
in a subset of patients exposed to BEAM, given that other
series of reduced-intensity transplantations in aggressive
NHL have consistently associated refractory disease at
transplantation with inferior outcomes [35,36]. An alterna-
tive explanation, however, is that the number of patients is
too small to enable identiﬁcation of this effect. A prior
autologous transplantation procedure has also been associ-
ated with increased risk of relapse and reduced OS in NHL
patients undergoing allogeneic transplantation [37]. In the
current series, only 4 patients had previously undergone
HDT/ASCT, preventing any conclusions regarding the impact
of prior transplantation on outcomes. In this cohort, there
was a trend towards improved PFS in younger patients
(<45 years) and OS in transplantation with a CMV-negative
donor and recipient.
A previous study reported that T cell depletion did not
inﬂuence the risk of infection or death from infection [15]. In
the current series, we observed a low rate of infectious
deaths. The NRM was 11% at 5 years, with infection
implicated in 3 deaths from NRM and in 1 patient with
encephalitis after relapse. CMV reactivationwas documented
in 7 patients. Poor performance status, as might be expected,and use of a VUD were associated with an increased risk of
NRM. The increased risk associated with use of a VUD is not
explained in this cohort by excessive GVHD. Acute GVHD
(grade II to IV) occurred in 15% of patients and was the
primary cause of death in 1. In keeping with other retro-
spective registry data, we failed to identify any correlation
between GVHD and risk of relapse, PFS, or OS [18,38,39]. This
could suggest that the GVL effect may exert lymphoma
control independent of GVHD, or perhaps that, in some
patients, the efﬁcacy of the conditioning regimen is
responsible for disease control. The unfavorable prognostic
impact of T cell phenotypewhen comparedwith aggressive B
cell NHL can be overcome by allogeneic SCT, with reduced
relapse rates and comparable OS reported [17,40,41]. Such
data provide support for the existence of GVL-mediated
disease control in PTCL. We observed no difference in
terms of outcome or relapse dependent on cell of origin seen
in the current series.
As improvements in initial therapy for DLBCL have
resulted in selection of more aggressive/chemo-resistant
clones at relapse, allogeneic SCT may become increasingly
important in the management of patients failing ﬁrst-line
therapy. Given the poor outcome of patients with DLBCL
refractory to or progressing within 12 months of immuno-
chemotherapy, eligible candidates are already considered
for allogeneic SCT as their ﬁrst transplantation procedure.
Prospective trials comparing the outcome of autologous and
allogeneic SCT in this setting are needed to allow conclusions
to be drawn. There is also a need to better identify the sub-
groups of patients with high-risk disease who would beneﬁt
from an allogeneic procedure as their ﬁrst transplantation,
given that < 20% of those relapsing after an autologous
transplantation actually receive an allogeneic SCT [18]. The
role of allogeneic SCT in the ﬁrst-line treatment of PTCL is
currently being investigated in a large European prospective
study (DSHNHL trial).
There remains a need to optimize conditioning regimens
based on patient and disease characteristics to improve
efﬁcacy while minimizing toxicity. There is also a role for
incorporation of novel agents and maintenance strategies
after transplantation to reduce relapse risk before the
emergence of a GVL effect.
The retrospective nature of this analysis of patients who
underwent transplantation over a time period in which the
role of transplantation in aggressive NHL has constantly
evolved makes drawing ﬁrm conclusions difﬁcult. Overall,
the data presented here support BEAM-Campath condition-
ing before allogeneic SCT as a regimen that is well tolerated
in patients with aggressive NHL and capable of delivering
durable remissions in a subset of patients. The high relapse
rate is indicative that further investigation is needed to allow
identiﬁcation of those patients most likely to beneﬁt.
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